231 related articles for article (PubMed ID: 16240686)
1. Regression of left ventricular hypertrophy in hypertension--does it reduce cardiovascular risk?
Braz Nogueira J
Rev Port Cardiol; 2005; 24(7-8):1007-13. PubMed ID: 16240686
[TBL] [Abstract][Full Text] [Related]
2. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension.
Pierdomenico SD; Lapenna D; Cuccurullo F
Am J Hypertens; 2008 Apr; 21(4):464-70. PubMed ID: 18369364
[TBL] [Abstract][Full Text] [Related]
3. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
Agabiti-Rosei E; Muiesan ML
J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
[TBL] [Abstract][Full Text] [Related]
4. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
Okin PM; Devereux RB; Liu JE; Oikarinen L; Jern S; Kjeldsen SE; Julius S; Wachtell K; Nieminen MS; Dahlöf B
J Hum Hypertens; 2004 Jun; 18(6):403-9. PubMed ID: 15057252
[TBL] [Abstract][Full Text] [Related]
5. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
Bang CN; Devereux RB; Okin PM
J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
[TBL] [Abstract][Full Text] [Related]
6. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
[TBL] [Abstract][Full Text] [Related]
7. The importance of left ventricular hypertrophy in human hypertension.
Kahan T
J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
[TBL] [Abstract][Full Text] [Related]
8. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
[TBL] [Abstract][Full Text] [Related]
9. [Left ventricular hypertrophy and cardiovascular risk in hypertension].
Amabile G
Ann Cardiol Angeiol (Paris); 1998 Feb; 47(2):86-90. PubMed ID: 9772934
[TBL] [Abstract][Full Text] [Related]
10. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
Okin PM
J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
[TBL] [Abstract][Full Text] [Related]
11. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
[TBL] [Abstract][Full Text] [Related]
12. Resistant hypertension and left ventricular hypertrophy: an overview.
Cuspidi C; Vaccarella A; Negri F; Sala C
J Am Soc Hypertens; 2010; 4(6):319-24. PubMed ID: 21130978
[TBL] [Abstract][Full Text] [Related]
13. Left ventricular hypertrophy in hypertensive patients in Indian primary care: prevalence and effect of treatment with sustained release indapamide.
Lokhandwala Y; Damle A
Curr Med Res Opin; 2004 May; 20(5):639-44. PubMed ID: 15140328
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular hypertrophy regression: the LIVE trial.
Sheridan DJ
Cardiologia; 1999 Dec; 44 Suppl 1(Pt 2):541-3. PubMed ID: 12497780
[TBL] [Abstract][Full Text] [Related]
15. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
Ruilope LM; Schmieder RE
Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
[TBL] [Abstract][Full Text] [Related]
16. Hypertensive heart disease--significance of left ventricular hypertrophy.
Schmieder RE
J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S50-5. PubMed ID: 1283190
[TBL] [Abstract][Full Text] [Related]
17. Is Left Ventricular Hypertrophy a Valid Therapeutic Target?
Brooks JE; Soliman EZ; Upadhya B
Curr Hypertens Rep; 2019 May; 21(6):47. PubMed ID: 31111289
[TBL] [Abstract][Full Text] [Related]
18. Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician?
Cuspidi C; Esposito A; Negri F; Sala C; Masaidi M; Giudici V; Zanchetti A; Mancia G
Am J Hypertens; 2008 Apr; 21(4):458-63. PubMed ID: 18369363
[TBL] [Abstract][Full Text] [Related]
19. Diastolic blood pressure reduction contributes more to the regression of left ventricular hypertrophy: a meta-analysis of randomized controlled trials.
Zhang K; Chen J; Liu Y; Wang T; Wang L; Wang J; Huang H
J Hum Hypertens; 2013 Nov; 27(11):698-706. PubMed ID: 23535988
[TBL] [Abstract][Full Text] [Related]
20. Clinical importance of detecting exaggerated blood pressure response to exercise on antihypertensive therapy.
Mizuno R; Fujimoto S; Saito Y; Yamazaki M
Heart; 2016 Jun; 102(11):849-54. PubMed ID: 26839069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
